Blueprint Still Confident In CDK2 Inhibitor Despite Partial Hold On Phase I/II Trial

 
• By Alaric DeArment

The FDA placed a partial hold on the VELA study of BLU-222 due to some patients experiencing visual toxicity, but the company anticipates reporting data and said it is near identifying Phase II dose.

Blueprint said the FDA placed a partial hold on its Phase I/II CDK2 inhibitor trial • Source: Shutterstock

More from Clinical Trials

More from R&D